VIVXF News and Press, Avivagen From 09/30/21

3Q21 Results. Avivagen reported revenue of $505,866 in the quarter, down from $612,530 last year. We had estimated revenue of $1.0 million. The majority of the miss comes from a 3.5 million tonne order shipped in the quarter for which the revenue has yet to be recognized. We estimate the delay...

Total of 8 tonnes in orders secured or shipped during the quarter Quarter represents more than 43% of 2020 fiscal year Avivagen Inc. (TSXV:VIV, OTCQB:VIVXF) (“Avivagen”), a life sciences corporation focused on developing and commercializing ...

Originally broadcast LIVE July 20, 2021. Avivagen CEO Kym Anthony makes a formal corporate presentation. Afterwards, he is joined by Noble Capital Markets Senior Research Analyst Joe Gomes for a Q & A session featuring questions asked by the live audience throughout the event. Read More &...

Drug-resistant superbugs have threatened human health for decades. The situation is getting worse because of the shortage of new antibiotics. But what if we changed the way we aim to treat them, and trained our cells to kill these invaders instead of relying on antibiotics to do the dirty work...

Addition of Mr. Lesley Nernberg brings technical sales and marketing expertise to Asia expansion efforts Termination of distribution agreement with São Paulo-based Look Chemicals creates opportunity for accelerated adoption of OxC-beta TM Livestock in Brazil ...

Multidrug resistance is a growing opportunity for investors interested in biotech. The modern world has been experiencing a dramatic decrease in the effectiveness of antimicrobial agents on bacterial pathogens. This is an emerging health problem according to the U.S. Center for Disease Control...

Avivagen Inc. (TSX.V: VIV) (OTCQB: VIVXF) is a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that, by safely supporting immune function, promote general health and performance. The corporation's unique OxC-...

Avivagen Inc. (TSXV:VIV, OTCQB:VIVXF) (“Avivagen”), a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that safely enhances feed intake and supports immune function, thereby supporting gener...

Avivagen (VIVXF) announces that it will be requesting approval from the TSX Venture Exchange to extend the expiry date of certain of its outstanding warrants.The warrants are exercisable to purchase 2.03M shares at $1.20/share and were originally issued on November 30, 2017, with ex...

Avivagen Inc. (TSXV:VIV, OTCQB:VIVXF) (“Avivagen” or the “Corporation”),a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that safely enhance and support immune function, ther...